Opposite effects of nicotinic acid and pyridoxine on systemic prostacyclin, thromboxane and leukotriene production in man

Pharmacology and Toxicology

Volumn 90, Issue 6, 2002, Pages 338-342

  Saareks, Virpi ^a,c   Ylitalo, Pauli ^a,c   Mucha, István ^b   Riutta, Asko ^a,d  

^a FIN 33014 Tampere ^*  (Finland)

^b Institute of Isotopes   (Hungary)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; 2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; BIOCHEMICAL MARKER; DRUG METABOLITE; HEKSAVIT; LEUKOTRIENE; LEUKOTRIENE E4; LIPOLYT RETARD; NICOTINIC ACID; PEPTIDOLEUKOTRIENE; PROSTACYCLIN; PYRIDOXINE; THROMBOXANE; 11 DEHYDRO THROMBOXANE B2; 11-DEHYDRO-THROMBOXANE B2; 2,3 DINOR 6 KETOPROSTAGLANDIN F1ALPHA; 2,3-DINOR-6-KETOPROSTAGLANDIN F1ALPHA; 6 OXOPROSTAGLANDIN F1 ALPHA; BIOLOGICAL MARKER; DRUG DERIVATIVE; THROMBOXANE B2;

ADULT; ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DRUG CROSS REACTIVITY; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; HUMAN EXPERIMENT; ICOSANOID METABOLISM; IMMUNOMODULATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; REFERENCE VALUE; SYSTEMIC CIRCULATION; URINARY EXCRETION; VITAMIN INTAKE; BIOSYNTHESIS; DELAYED RELEASE FORMULATION; ENZYME IMMUNOASSAY; ORAL DRUG ADMINISTRATION; URINE;

6-KETOPROSTAGLANDIN F1 ALPHA; ADMINISTRATION, ORAL; ADULT; BIOLOGICAL MARKERS; DELAYED-ACTION PREPARATIONS; HUMAN; IMMUNOENZYME TECHNIQUES; LEUKOTRIENE E4; MALE; NIACIN; PYRIDOXINE; SUPPORT, NON-U.S. GOV'T; THROMBOXANE B2; HUMANS;

EID: 0036018540     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2002.900608.x     Document Type: Article

References (41)

1. Hyperhomocysteinemia in type 2 diabetes mellitus: Cardiovascular risk factors and effect of treatment with folic acid and pyridoxine
2. 2 is a potent contractile agonist of human and guinea pig airways
3. Niacin dosing: Relationship to benefits and adverse effects
4. Nicotinic acid: Its metabolism and its effects on plasma free fatty acids
5. Efficacy and safety of one-year treatment with slow-release nicotinic acid. Monitoring of drug concentration in serum
6. Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus
7. Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: An update. Part I: Synthesis, receptors and role of leukotrienes in asthma
8. Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: An update. Part II: Clinical studies with leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma
9. 6 metabolism in man
10. Niacin-induced hepatitis: A potential side effect with low-dose time-release niacin
11. Analysis of eicosanoid formation in humans by mass spectrometry
12. Platelet activation in unstable coronary artery disease
13. 2 biosynthesis in cardiovascular disease
14. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia
15. Assay of urinary prostanoids
16. Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men
17. Evaluating niacin in its various forms
18. Possible mechanism of pyridoxal-5′-phosphate inhibition of ADP-induced aggregation
19. Increased thromboxane biosynthesis in patients with acute cerebral ischemia
20. 4 in humans
21. Transient focal hepatic defects related to sustained-release niacin
22. A comparison of the efficacy and toxic effects of sustained- vs immediate release niacin in hypercholesterolemic patients
23. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation
24. 2 release following oral administration of niacin in humans
25. 2 in vivo in humans following the administration of nicotinic acid
26. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid
27. 4 in human urine
28. 2 in human urine and plasma by gas chromatography-mass spectrometry
29. 2 metabolite excretion after thrombolysis
30. Eicosanoid biosynthesis and platelet function with advancing age
31. Depressed plasma pyridoxal phosphate concentrations in adult asthmatics
32. 2 for reliable determination with radioimmunoassay
33. 1α for determination with radioimmunoassay
34. Nicotinic acid and pyridoxine modulate arachidonic acid metabolism in vitro and ex vivo in man
35. Sensory neuropathy from pyridoxine abuse, a new megavitamin syndrome
36. Effect of pyridoxal-5′-phosphate on human neutrophil aggregation in vitro
37. Comparison of antioxidant and nonantioxidant lipoxygenase inhibitors on neutrophil function. Implication for pathogenesis of myocardial reperfusion injury
38. Pyridoxine-induced inhibition of platelet aggregation and the release reaction
39. The in vivo effect in humans of pyridoxal-5′-phosphate on platelet function and blood coagulation
40. Thromboxane and prostacyclin formation in patients with deep vein thrombosis
41. 4